FDA Grants Accelerated Approval to Rubraca for Advanced Ovarian Cancer

The FDA has granted accelerated approval to rucaparib to treat women with a certain type of ovarian cancer. Rucaparib is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation , as identified by an FDA-approved companion diagnostic test.